Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical ...

Earlier this year, Eshelman Innovation and the North Carolina Biotechnology Center hosted the 2024 N.C. Radiopharmaceuticals ...

Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.

The 11,000-square-foot condo, located on the top two floors of the 57-story tower, offers views of the water and the Miami ...

Bob Duggan is cashing in on a 689% rally in his Summit Therapeutics Inc. to buy one of the most expensive condos ever sold in Miami’s Brickell neighborhood.Duggan is buying a $33 million two-story ...

BPGbio's TPD program is at the forefront of this breakthrough, utilizing E2s to drive the development of innovative bifunctional degraders and monovalent molecular glues, opening new frontiers in drug ...

To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

Bob Duggan, chairman and co-CEO of Summit Therapeutics Inc. SMMT, is capitalizing on a remarkable 689% stock surge to ...

The billionaire founder and CEO of Summit Pharmaceuticals and his partner/co-CEO paid $33 million for a penthouse in Miami’s ...

Oncotelic's Cautionary Note on Forward-Looking Statements ...

On Monday, Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $20.5 which represents a decrease of $-0.71 or -3.35% from the prior close of $21.21. The stock opened at $21.16 and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.